Advertisement

NeuroMolecular Medicine

, Volume 10, Issue 1, pp 10–16 | Cite as

Nonsynonymous Polymorphisms of Histamine-Metabolising Enzymes in Patients with Parkinson’s Disease

  • José A. G. Agúndez
  • Antonio Luengo
  • Oscar Herráez
  • Carmen Martínez
  • Hortensia Alonso-Navarro
  • Félix Javier Jiménez-Jiménez
  • Elena García-MartínEmail author
Original Paper

Abstract

Objective    To analyze genetically based impairment in histamine-metabolising enzymes in patients with Parkinson’s disease (PD). Methods    Leukocytary DNA from 214 PD patients and a control group of 295 unrelated healthy individuals was studied for nonsynonymous histamine N-methyltransferase (HNMT) and diamine oxidase (ABP1) polymorphisms by using amplification–restriction analyses. Results    An association of the HNMT Thr105Ile polymorphism, but not of the ABP1 His645Asp polymorphism, with PD was observed. Patients with PD showed a higher frequency of homozygous HNMT genotypes leading to high activity with a gene-dose effect (P < 0.001), as compared to healthy subjects. These findings were independent of gender, but the association with the HNMT polymorphism is higher among patients with late-onset PD (P < 0.0001). Conclusion    These results, combined with previous findings indicating alterations in histamine levels in patients with PD, suggest that alterations of histamine homeostasis in the SNC are associated with the risk for PD.

Keywords

Parkinson’s disease Histamine HNMT DAO ABP1 

Notes

Acknowledgements

This work was supported in part by Grants SAF 2003–00967 from Ministerio de Ciencia y Tecnología, FIS 05/1056 and 06/1252 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III.

References

  1. Abbas, N., Lucking, C. B., Ricard, S., Durr, A., Bonifati, V., De Michele, G., Bouley, S., Vaughan, J. R., Gasser, T., Marconi, R., Broussolle, E., Brefel-Courbon, C., Harhangi, B. S., Oostra, B. A., Fabrizio, E., Bohme, G. A., Pradier, L., Wood, N. W., Filla, A., Meco, G., Denefle, P., Agid, Y., & Brice, A. (1999). A wide variety of mutations in the parkin gene are responsible for autosomal recessive Parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease. Human Molecular Genetics, 8, 567–574.PubMedCrossRefGoogle Scholar
  2. Abeliovich, A., & Flint Beal, M. (2006). Parkinsonism genes: Culprits and clues. Journal of Neurochemistry, 99, 1062–1072.PubMedCrossRefGoogle Scholar
  3. Agundez, J. A., Jimenez-Jimenez, F. J., Luengo, A., Bernal, M. L., Molina, J. A., Ayuso, L., Vazquez, A., Parra, J., Duarte, J., Coria F., et al. (1995). Association between the oxidative polymorphism and early onset of Parkinson’s disease. Clinical Pharmacology and Therapeutics, 57, 291–298.PubMedGoogle Scholar
  4. Agundez, J. A., Jimenez-Jimenez F. J., Luengo A., Molina J. A., Orti-Pareja M., Vazquez A., Ramos F., Duarte J., Coria F., Ladero J. M., Alvarez-Cermeno J. C., & Benitez J. (1998). Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson’s disease. Neurology, 51, 1587–1592.PubMedGoogle Scholar
  5. Agundez, J. A., Rodriguez I., Olivera M., Ladero J. M., Garcia M. A., Ribera J. M., & Benitez J. (1997). CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing, 26, 147–151.PubMedCrossRefGoogle Scholar
  6. Anichtchik, O. V., Rinne, J. O., Kalimo, H., & Panula, P. (2000). An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Experimental Neurology, 163, 20–30.PubMedCrossRefGoogle Scholar
  7. Ayuso, P., Garcia-Martin, E., Martinez, C., & Agundez, J. A. (2007). Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. Pharmacogenet Genomics, 17, 687–693.PubMedGoogle Scholar
  8. Bonifati, V., Fabrizio, E., Vanacore, N., De Mari, M., & Meco, G. (1995). Familial Parkinson’s disease: A clinical genetic analysis. The Canadian Journal of Neurological Sciences, 22, 272–279.PubMedGoogle Scholar
  9. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J. W., Vanacore, N., van Swieten, J. C., Brice, A., Meco, G., van Duijn, C. M., Oostra, B. A., & Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256–259.PubMedCrossRefGoogle Scholar
  10. Brennan, P. (2002). Gene–environment interaction and aetiology of cancer: What does it mean and how can we measure it? Carcinogenesis, 23, 381–387.PubMedCrossRefGoogle Scholar
  11. Chade, A. R., Kasten, M., & Tanner, C. M. (2006). Nongenetic causes of Parkinson’s disease. Journal of Neural Transmission, Suppl, 147–151.Google Scholar
  12. Chan, D. K., Lam, M. K., Wong, R., Hung, W. T., & Wilcken, D. E. (2003). Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology, 60, 1002–1005.PubMedGoogle Scholar
  13. Clarimon, J., Scholz, S., Fung, H. C., Hardy, J., Eerola, J., Hellstrom, O., Chen, C. M., Wu, Y. R., Tienari, P. J., & Singleton, A. (2006). Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. American Journal of Human Genetics, 78, 1082–1084; author reply 1092–1094.Google Scholar
  14. Coelho, M. H., Silva, I. J., Azevedo, M. S., & Manso, C. F. (1991). Decrease in blood histamine in drug-treated parkinsonian patients. Molecular and Chemical Neuropathology, 14, 77–85.PubMedCrossRefGoogle Scholar
  15. Daly, A. K., & Day, C. P. (2001). Candidate gene case–control association studies: Advantages and potential pitfalls. British Journal of Clinical Pharmacology, 52, 489–499.PubMedCrossRefGoogle Scholar
  16. de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997). Prevalence of Parkinsonism and Parkinson’s disease in Europe: The EUROPARKINSON Collaborative Study. European community concerted action on the epidemiology of Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 62, 10–15.PubMedCrossRefGoogle Scholar
  17. Dekker, M. C., Bonifati, V., & van Duijn C. M. (2003). Parkinson’s disease: Piecing together a genetic jigsaw. Brain, 126, 1722–1733.PubMedCrossRefGoogle Scholar
  18. Elbaz, A., Grigoletto, F., Baldereschi, M., Breteler, M. M., Manubens-Bertran, J. M., Lopez-Pousa, S., Dartigues, J. F., Alperovitch, A., Tzourio, C., & Rocca, W. A. (1999). Familial aggregation of Parkinson’s disease: A population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology, 52, 1876–1882.PubMedGoogle Scholar
  19. Elbaz, A., Nelson, L. M., Payami, H., Ioannidis, J. P., Fiske, B. K., Annesi, G., Carmine Belin, A., Factor, S. A., Ferrarese, C., Hadjigeorgiou, G. M., Higgins, D. S., Kawakami, H., Kruger, R., Marder, K. S., Mayeux, R. P., Mellick, G. D., Nutt, J. G., Ritz, B., Samii, A., Tanner, C. M., Van Broeckhoven, C., Van Den Eeden S. K., Wirdefeldt, K., Zabetian, C. P., Dehem, M., Montimurro, J. S., Southwick, A., Myers, R. M., & Trikalinos, T. A. (2006). Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson’s disease: A large-scale international study. Lancet Neurology, 5, 917–923.PubMedCrossRefGoogle Scholar
  20. Farrer, M. J., Haugarvoll, K., Ross, O. A., Stone, J. T., Milkovic, N. M., Cobb, S. A., Whittle, A. J., Lincoln, S. J., Hulihan, M. M., Heckman, M. G., White, L. R., Aasly, J. O., Gibson, J. M., Gosal, D., Lynch, T., Wszolek, Z. K., Uitti, R. J., & Toft, M. (2006). Genomewide association, Parkinson disease, and PARK10. American Journal of Human Genetics, 78, 1084–1088; author reply 1092–1094.Google Scholar
  21. Fearnley, J. M., & Lees, A. J. (1991). Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain, 114(Pt 5), 2283–2301.Google Scholar
  22. Funayama, M., Hasegawa K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002). A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of Neurology, 51, 296–301.PubMedCrossRefGoogle Scholar
  23. Gasser, T., Muller-Myhsok, B., Wszolek, Z. K., Oehlmann, R., Calne, D. B., Bonifati, V., Bereznai, B., Fabrizio, E., Vieregge, P., & Horstmann, R. D. (1998). A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nature Genetics, 18, 262–265.PubMedCrossRefGoogle Scholar
  24. Gibb, W. R., & Lees, A. J. (1989). Prevalence of Lewy bodies in Alzheimer’s disease. Annals of Neurology, 26, 691–693.PubMedCrossRefGoogle Scholar
  25. Goris, A., Williams-Gray, C. H., Foltynie, T., Compston, D. A., Barker, R. A., & Sawcer, S. J. (2006). No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. American Journal of Human Genetics, 78, 1088–1090; author reply 1092–1094.Google Scholar
  26. Hampshire, D. J., Roberts, E., Crow, Y., Bond, J., Mubaidin, A., Wriekat, A. L., Al-Din, A., & Woods, C. G. (2001). Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. Journal of Medical Genetics, 38, 680–682.PubMedCrossRefGoogle Scholar
  27. Hardy, J., Cai, H., Cookson, M. R., Gwinn-Hardy, K., & Singleton, A. (2006). Genetics of Parkinson’s disease and parkinsonism. Annals of Neurology, 60, 389–398.PubMedCrossRefGoogle Scholar
  28. Hicks, A. A., Petursson, H., Jonsson, T., Stefansson, H., Johannsdottir, H. S., Sainz, J., Frigge, M. L., Kong, A., Gulcher, J. R., Stefansson, K., & Sveinbjornsdottir, S. (2002). A susceptibility gene for late-onset idiopathic Parkinson’s disease. Annals of Neurology, 52, 549–555.PubMedCrossRefGoogle Scholar
  29. Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry, 55, 181–184.PubMedGoogle Scholar
  30. Jimenez-Jimenez, F. J., Tabernero, C., Mena, M. A., Garcia de Yebenes, J., Garcia de Yebenes, M. J., Casarejos, M. J., Pardo, B., Garcia-Agundez, J. A., Benitez, J., Martinez, A., et al. (1991). Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. Journal Neurochemistry, 57, 81–87.CrossRefGoogle Scholar
  31. Kim, S. H., Krapfenbauer, K., Cheon, M. S., Fountoulakis, M., Cairns, N. J., & Lubec, G. (2002). Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick’s disease. Neuroscience Letters, 321, 169–172.PubMedCrossRefGoogle Scholar
  32. Langlais, P. J., Zhang, S. X., Weilersbacher, G., Hough, L. B., & Barke, K. E. (1994). Histamine-mediated neuronal death in a rat model of Wernicke’s encephalopathy. Journal of Neuroscience Research, 38, 565–574.PubMedCrossRefGoogle Scholar
  33. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P. J., Wilkinson, K. D., & Polymeropoulos, M. H. (1998). The ubiquitin pathway in Parkinson’s disease. Nature, 395, 451–452.PubMedCrossRefGoogle Scholar
  34. Li, Y., Rowland, C., Schrodi, S., Laird, W., Tacey, K., Ross, D., Leong, D., Catanese, J., Sninsky, J., & Grupe, A. (2006). A case-control association study of the 12 single-nucleotide polymorphisms implicated in Parkinson disease by a recent genome scan. American Journal of Human Genetics, 78, 1090–1092; author reply 1092–1094.Google Scholar
  35. Maraganore, D. M., de Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca, W. A., Pant, P. V., Frazer, K. A., Cox, D. R., & Ballinger, D. G. (2005). High-resolution whole-genome association study of Parkinson disease. American Journal of Human Genetics, 77, 685–693.PubMedCrossRefGoogle Scholar
  36. Marder, K., Tang, M. X., Mejia, H., Alfaro, B., Cote, L., Louis, E., Groves, J., & Mayeux, R. (1996). Risk of Parkinson’s disease among first-degree relatives: A community-based study. Neurology, 47, 155–160.PubMedGoogle Scholar
  37. Matsumine, H., Saito, M., Shimoda-Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., Igarashi, S., Takano, H., Sanpei, K., Koike, R., Mori, H., Kondo, T., Mizutani, Y., Schaffer, A. A., Yamamura, Y., Nakamura, S., Kuzuhara, S., Tsuji, S., & Mizuno, Y. (1997). Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2–27. American Journal of Human Genetics, 60, 588–596.PubMedGoogle Scholar
  38. Obata, T. (2002). Semicarbazide-sensitive amine oxidase (SSAO) in the brain. Neurochemical Research, 27, 263–268.PubMedCrossRefGoogle Scholar
  39. Pankratz, N., Nichols, W. C., Uniacke, S. K., Halter, C., Rudolph, A., Shults, C., Conneally, P. M., & Foroud, T. (2003). Significant linkage of Parkinson disease to chromosome 2q36–37. American Journal of Human Genetics, 72, 1053–1057.PubMedCrossRefGoogle Scholar
  40. Panula, P., Yang, H. Y., & Costa, E. (1984). Histamine-containing neurons in the rat hypothalamus. Proceedings of the National Academy of Sciences of the United States of America, 81, 2572–2576.PubMedCrossRefGoogle Scholar
  41. Pértegas Díazs, S., & Pita Fernández, S. (2003). Cálculo del poder estadístico de un estudio. Cad Aten Prim, 10, 59–63.Google Scholar
  42. Piccini, P., Burn, D. J., Ceravolo, R., Maraganore, D., & Brooks, D. J. (1999). The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Annals of Neurology, 45, 577–582.PubMedCrossRefGoogle Scholar
  43. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di, Iorio, G., Golbe, L. I., & Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276, 2045–2047.PubMedCrossRefGoogle Scholar
  44. Prell, G. D., & Green, J. P. (1991). Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions Supplement, 33, 343–363.Google Scholar
  45. Preuss, C. V., Wood, T. C., Szumlanski, C. L., Raftogianis, R. B., Otterness, D. M., Girard, B., Scott, M. C., & Weinshilboum, R. M. (1998). Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Molecular Pharmacology, 53, 708–717.PubMedGoogle Scholar
  46. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., & Gwinn-Hardy, K. (2003). Alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 302, 841.PubMedCrossRefGoogle Scholar
  47. Tan, E. K., Chan, D. K., Ng, P. W., Woo, J., Teo, Y. Y., Tang, K., Wong, L. P., Chong, S. S., Tan, C., Shen, H., Zhao, Y., & Lee, C. G. (2005). Effect of MDR1 haplotype on risk of Parkinson disease. Archives of Neurology, 62, 460–464.PubMedCrossRefGoogle Scholar
  48. Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., & Langston, J. W. (1999). Parkinson disease in twins: an etiologic study. The Journal of American Medical Association, 281, 341–346.CrossRefGoogle Scholar
  49. Thoburn, K. K., Hough, L. B., Nalwalk, J. W., & Mischler, S. A. (1994). Histamine-induced modulation of nociceptive responses. Pain, 58, 29–37.PubMedCrossRefGoogle Scholar
  50. Thomas, B., & Prell, G. D. (1995). Imidazoleacetic acid, a gamma-aminobutyric acid receptor agonist, can be formed in rat brain by oxidation of histamine. Journal of Neurochemisry, 65, 818–826.CrossRefGoogle Scholar
  51. Valente, E. M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A. E., Caputo, V., Romito, L., Albanese, A., Dallapiccola, B., & Bentivoglio, A. R. (2004). PINK1 mutations are associated with sporadic early-onset parkinsonism. Annals of Neurology, 56, 336–341.PubMedCrossRefGoogle Scholar
  52. van Duijn, C. M., Dekker, M. C., Bonifati, V., Galjaard, R. J., Houwing-Duistermaat, J. J., Snijders, P. J., Testers, L., Breedveld, G. J., Horstink, M., Sandkuijl, L. A., van Swieten, J. C., Oostra, B. A., & Heutink, P. (2001). Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. American Journal of Human Genetics, 69 , 629–634.PubMedCrossRefGoogle Scholar
  53. Vizuete, M. L., Merino, M., Venero, J. L., Santiago, M., Cano, J., & Machado, A. (2000). Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra. Journal of Neurochemistry, 75, 540–552.PubMedCrossRefGoogle Scholar
  54. Watanabe, T., Taguchi, Y., Shiosaka, S., Tanaka, J., Kubota, H., Terano, Y., Tohyama, M., & Wada, H. (1984). Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Research, 295, 13–25.PubMedCrossRefGoogle Scholar
  55. Wilk, J. B., Tobin, J. E., Suchowersky, O., Shill, H. A., Klein, C., Wooten, G. F., Lew, M. F., Mark, M. H., Guttman, M., Watts, R. L., Singer, C., Growdon, J. H., Latourelle, J. C., Saint-Hilaire, M. H., DeStefano, A. L., Prakash, R., Williamson, S., Berg, C. J., Sun, M., Goldwurm, S., Pezzoli, G., Racette, B. A., Perlmutter, J. S., Parsian, A., Baker, K. B., Giroux, M. L., Litvan, I., Pramstaller, P. P., Nicholson, G., Burn, D. J., Chinnery, P. F., Vieregge, P., Slevin, J. T., Cambi, F., MacDonald, M. E., Gusella, J. F., Myers, R. H., & Golbe, L. I. (2006). Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. Neurology, 67, 2206–2210.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • José A. G. Agúndez
    • 1
  • Antonio Luengo
    • 2
  • Oscar Herráez
    • 1
  • Carmen Martínez
    • 1
  • Hortensia Alonso-Navarro
    • 3
  • Félix Javier Jiménez-Jiménez
    • 3
  • Elena García-Martín
    • 4
    Email author
  1. 1.Department of Pharmacology & Psychiatry, Medical SchoolUniversity of ExtremaduraBadajozSpain
  2. 2.Service of Neurology University Hospital La PrincesaMadridSpain
  3. 3.Department of Medicine—NeurologyPríncipe de Asturias Hospital, University of Alcalá de HenaresMadridSpain
  4. 4.Department of Biochemistry and Molecular Biology, School of Biological SciencesUniversity of ExtremaduraBadajozSpain

Personalised recommendations